AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 182
Study 31290763 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of cavity shave margins (CSM)
Number of subjects: 396
Study 31290763 — intervention group
Group type: COMPARATOR
Intervention: No resection of cavity shave margins (no shave)
Number of subjects: 396
Study 31647577 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg DFN-15
Number of subjects: 622
Study 29683391 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 300 mg
Number of subjects: 9
Study 29683391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26979136 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/14
Number of subjects: 168
Study 26979136 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/28
Number of subjects: 168
Study 26979136 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/14/28
Number of subjects: 168
Study 26979136 — intervention group
Group type: EXPERIMENTAL
Intervention: half dose AV7909 on Days 0/14/28
Number of subjects: 168
Study 26979136 — intervention group
Group type: COMPARATOR
Intervention: BioThrax vaccine on Days 0/14/28
Number of subjects: 168
Study 25494177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat suture closure
Number of subjects: 116
Study 25494177 — intervention group
Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 116
Study 22209361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 mg
Number of subjects: 766
Study 22209361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 10 mg
Number of subjects: 766
Study 22209361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 2.5 mg
Number of subjects: 766
Study 22209361 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 766
Study 22209361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 20177281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture specific for depression
Number of subjects: 150
Study 20177281 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 150
Study 20177281 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 150
Study 17982558 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EAC)
Number of subjects: 24
Study 17982558 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 16125515 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week rehabilitation program including individual exercise, sports, psycho-education, and information
Number of subjects: 63
Study 12137819 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral dilation with Benique dilatators (maximal 21F) under intraurethral anesthesia, starting 10 days after initial DVIU, protocol: weekly for the first month, once after 3 and 6 months, then annually.
Number of subjects: 37
Study 12137819 — intervention group
Group type: COMPARATOR
Intervention: Consecutive DVIUs considered when stricture recurred after initial DVIU.
Number of subjects: 37
Study 12137819 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal urinary flow rate at last follow-up.
Number of subjects: 37
Study 10655186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 0.1% drops
Number of subjects: 87
Study 10655186 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% drops
Number of subjects: 87
Study 10655186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 0.1% drops and Sodium chloride 0.9% drops
Number of subjects: 87
Study 8653256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse First (NF)
Number of subjects: 2000
Study 8653256 — intervention group
Group type: COMPARATOR
Intervention: Doctor First (DF)
Number of subjects: 2000
Study 1944438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (20 mg/kg, orally, four times daily for five days)
Number of subjects: 815
Study 1944438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 815
Study 1944438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 6686118 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade (50 mg oral metoprolol or 40 mg oral propranolol, each twice per day)
Number of subjects: 17
Study 6686118 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 6686118 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade (metoprolol)
Number of subjects: 17
Study 6686118 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade (propranolol)
Number of subjects: 17
Study 6686118 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 17
Study 31797987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal micronutrient supplementation
Number of subjects: 1388
Study 28107273 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 55
Number of subjects: 12
Study 28107273 — intervention group
Group type: COMPARATOR
Intervention: BIS 25
Number of subjects: 12
Study 26628417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant participants (n=63 pregnancies)
Number of subjects: 452
Study 26628417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant participants (n=53 pregnancies)
Number of subjects: 452
Study 26628417 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-born infants (n=39)
Number of subjects: 452
Study 25136625 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter-based breakfast
Number of subjects: 0
Study 25136625 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine-based breakfast
Number of subjects: 0
Study 25136625 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based breakfast
Number of subjects: 0
Study 25136625 — intervention group
Group type: COMPARATOR
Intervention: All breakfast types
Number of subjects: 0
Study 23160696 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/ml ropivacaine (group A, 42 patients)
Number of subjects: 86
Study 23160696 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/ml levobupivacaine (group B, 44 patients)
Number of subjects: 86
Study 19465290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐piece AcrySof MA60BM IOL implanted in the capsular bag
Number of subjects: 14
Study 19465290 — intervention group
Group type: COMPARATOR
Intervention: 3‐piece AcrySof MA60BM IOL implanted in the ciliary sulcus with optic captured through PCCC
Number of subjects: 14
Study 17469891 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and acceptance and commitment therapy (ACT)
Number of subjects: 81
Study 17469891 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 81
Study 15660859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation 4 mg/kg per day
Number of subjects: 24
Study 15660859 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral iron supplementation)
Number of subjects: 24
Study 10782187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Loss Prevention Program (HLPP)
Number of subjects: 44547
Study 9058176 — intervention group
Group type: EXPERIMENTAL
Intervention: Support availability condition
Number of subjects: 49
Study 9058176 — intervention group
Group type: COMPARATOR
Intervention: No support availability condition
Number of subjects: 49
Study 8367728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple trauma rehabilitation
Number of subjects: 104
Study 3094411 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cromolyn
Number of subjects: 5
Study 3094411 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 3177551 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 0
Study 3177551 — intervention group
Group type: COMPARATOR
Intervention: Genetic amniocentesis
Number of subjects: 0
Study 31526014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (0.8 mSv)
Number of subjects: 19
Study 31526014 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (4.2 mSv)
Number of subjects: 19
Study 31405924 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg amisulpride
Number of subjects: 60
Study 31405924 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg propranolol
Number of subjects: 60
Study 31405924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28532881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm Release
Number of subjects: 17
Study 25492246 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathlon CS TKA
Number of subjects: 31
Study 25492246 — intervention group
Group type: COMPARATOR
Intervention: Triathlon PS TKA
Number of subjects: 31
Study 23009193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus alteplase
Number of subjects: 119
Study 23009193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 119
Study 23009193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 21667089 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 20
Study 21667089 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 20
Study 21667089 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 18088241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine for 52 weeks
Number of subjects: 151
Study 18088241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine for at least 2 years
Number of subjects: 151
Study 18088241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 18088241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (previous treatment)
Number of subjects: 151
Study 18088241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 151
Study 17070256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-shock wave lithotripsy 6Fr Double-J stent
Number of subjects: 186
Study 17070256 — intervention group
Group type: COMPARATOR
Intervention: No stent
Number of subjects: 186
Study 15172892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin for 4 months
Number of subjects: 58
Study 15172892 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid for 9 months
Number of subjects: 58
Study 11026174 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about suicide risk and urging to remove guns from the home
Number of subjects: 106
Study 11026174 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study 9315793 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV during NREM sleep
Number of subjects: 6
Study 9315793 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV during REM sleep
Number of subjects: 6
Study 9315793 — intervention group
Group type: COMPARATOR
Intervention: NPPV vs control-sham on sleep efficiency
Number of subjects: 6
Study 9315793 — intervention group
Group type: COMPARATOR
Intervention: NPPV vs control-sham on total sleep time (TST)
Number of subjects: 6
Study 9315793 — intervention group
Group type: COMPARATOR
Intervention: NPPV vs control-sham on sleep architecture
Number of subjects: 6
Study 9315793 — intervention group
Group type: COMPARATOR
Intervention: NPPV vs control-sham on number of arousals
Number of subjects: 6
Study 8113478 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 75
Study 8113478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy (RT)
Number of subjects: 75
Study 8113478 — intervention group
Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 75
Study 3750071 — intervention group
Group type: EXPERIMENTAL
Intervention: Knodt Rods
Number of subjects: 24
Study 3750071 — intervention group
Group type: COMPARATOR
Intervention: No Knodt Rods (Control)
Number of subjects: 24
Study 30993928 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention treatment
Number of subjects: 23
Study 28924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Magnifier (VM) added to standard vision rehabilitation (VR)
Number of subjects: 37
Study 28924412 — intervention group
Group type: COMPARATOR
Intervention: Standard vision rehabilitation (VR)
Number of subjects: 37
Study 28924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VM and VR)
Number of subjects: 37
Study 26320858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 26320858 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 26320858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26320858 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 26320858 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 23515115 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based stroke education program
Number of subjects: 36
Study 23515115 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 36
Study 21196761 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen honey (BPH)
Number of subjects: 44
Study 21196761 — intervention group
Group type: COMPARATOR
Intervention: Regular honey (RH)
Number of subjects: 44
Study 21196761 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual allergy medication)
Number of subjects: 44
Study 18070004 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) and bright-light therapy (1 hour of morning light exposure at > or = 2,500 lux)
Number of subjects: 50
Study 18070004 — intervention group
Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 50
Study 16527014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray (0.05% concentration, one spray in each nostril, three times a day for 5 days)
Number of subjects: 60
Study 12866606 — intervention group
Group type: EXPERIMENTAL
Intervention: CI‐1023 (Ad(GV)VEGF121.10), a replication‐deficient adenovirus encoding human vascular endothelial growth factor isoform 121, administered via intramuscular injection (4 x 10(8) to 4 x 10(10) particle units)
Number of subjects: 15
Study 12866606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11324805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 35
Study 11324805 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 35
Study 9340057 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Carboplatine, Etoposide, Vincristine, 6 courses, 3-week basis)
Number of subjects: 62
Study 9340057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (same chemotherapy regimen + primary site irradiation, total dose 40Gy)
Number of subjects: 62
Study 9340057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 62
Study 8349471 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF (40 mg in a single sublingual dose)
Number of subjects: 40
Study 8349471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2882966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (1000 mg, Pentasa)
Number of subjects: 123
Study 2882966 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (25 mg)
Number of subjects: 123
Study 29691246 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBack model of care (MOC)
Number of subjects: 0
Study 29691246 — intervention group
Group type: COMPARATOR
Intervention: Current routine care
Number of subjects: 0
Study 28716522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) individualized by TRIMPi method
Number of subjects: 22
Study 28716522 — intervention group
Group type: COMPARATOR
Intervention: Usual care (SOC)
Number of subjects: 22
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 40 mg
Number of subjects: 0
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 10 mg
Number of subjects: 0
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg
Number of subjects: 0
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 5 mg
Number of subjects: 0
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 2.5 mg
Number of subjects: 0
Study 26179482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26179482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (all doses)
Number of subjects: 0
Study 23922170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity eccentric exercise (initial bout)
Number of subjects: 16
Study 23922170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity eccentric exercise (second bout)
Number of subjects: 16
Study 23922170 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (no exercise)
Number of subjects: 16
Study 21441078 — intervention group
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg administered 3-times daily for 28 days
Number of subjects: 157
Study 21441078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 18202030 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Number of subjects: 86
Study 18202030 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 86
Study 16552404 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss programme with long-chain n-3 polyunsaturated fatty acids (WLFO)
Number of subjects: 116
Study 16552404 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss programme with placebo oil (WLPO)
Number of subjects: 116
Study 16552404 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo oil, no weight-loss programme)
Number of subjects: 116
Study 12668587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic activity (measured by renal norepinephrine spillover)
Number of subjects: 0
Study 12668587 — intervention group
Group type: COMPARATOR
Intervention: Heart failure (high sympathetic tone)
Number of subjects: 0
Study 12668587 — intervention group
Group type: COMPARATOR
Intervention: Pure autonomic failure (low sympathetic activity)
Number of subjects: 0
Study 12668587 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging (reduced epinephrine secretion)
Number of subjects: 0
Study 11327291 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rehabilitation programme including balance and coordination training
Number of subjects: 40
Study 11327291 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I with posterior fossa tumour)
Number of subjects: 40
Study 11327291 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II with cerebellopontine angle tumour)
Number of subjects: 40
Study 8829860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 132
Study 8829860 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 132
Study 8829860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 132
Study 8829860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 132
Study 8829860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 1905361 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (1 ml of a 2% solution)
Number of subjects: 33
Study 1905361 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (2.5 gm of a 10% ointment)
Number of subjects: 33
Study 1905361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6347521 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation algorithm (protocol group)
Number of subjects: 603
Study 6347521 — intervention group
Group type: COMPARATOR
Intervention: No algorithm (control group)
Number of subjects: 603
Study 31187674 — intervention group
Group type: EXPERIMENTAL
Intervention: Luo Han Guo decoction (30 mL administered starting 6 hours after surgery)
Number of subjects: 203
Study 31187674 — intervention group
Group type: COMPARATOR
Intervention: Control group (black tea)
Number of subjects: 203
Study 31187674 — intervention group
Group type: EXPERIMENTAL
Intervention: Luo Han Guo decoction
Number of subjects: 203
Study 29466107 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 148
Study 29466107 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care as Usual (E‐CAU)
Number of subjects: 148
Study 25559811 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine and cisplatin (XP)
Number of subjects: 458
Study 25559811 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (XPRT)
Number of subjects: 458
Study 25559811 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 458
Study 23567482 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Number of subjects: 75
Study 23567482 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Number of subjects: 75
Study 23567482 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mL IV normal saline as placebo)
Number of subjects: 75
Study 23567482 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive acetaminophen (15 mg/kg IV)
Number of subjects: 75
Study 23567482 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive acetaminophen (15 mg/kg IV)
Number of subjects: 75
Study 22207070 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT in spastic muscle
Number of subjects: 15
Study 22207070 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT in spastic muscle + rESWT in antagonist muscle
Number of subjects: 15
Study 22207070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19955891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 3 microg/kg
Number of subjects: 66
Study 19955891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral pantoprazole 40 mg)
Number of subjects: 66